U.S., June 26 -- ClinicalTrials.gov registry received information related to the study (NCT07035886) titled 'A Study to Monitor the Fruzaqla Treatment of Adults With Metastatic Colorectal Cancer (mCRC) in South Korea' on June 17.
Brief Summary: The purpose of this study is to estimate the proportion of all adverse events (AEs) including serious adverse events (SAEs) occurring with the use of fruquintinib among adult participants who have been administered fruquintinib as per the approved indications.
Study Start Date: Nov. 30, 2025
Study Type: OBSERVATIONAL
Condition:
Colorectal Cancer
Intervention:
OTHER: No intervention
As this is an observational study, no intervention will be administered.
Recruitment Status: NOT_YET_RECRUITING...